Purpose
The tumor microenvironment (TME) is immunosuppressive and presents many challenges to cancer therapies. Modulating TME to be less immunosuppressive will block tumor immune escape and enhance the effects of cancer immunotherapies such as T-cell therapies. However, TME modulating agents need to be selectively delivered to the tumors to protect them from degradation and inducing unwanted toxicity to healthy organs. This project will develop novel nanoparticle systems containing TME modulating messenger RNA (mRNA) and selectively deliver them to tumors to modulate the TME. The team will assess the therapeutic effects of our mRNA-nanoparticle systems in clinically relevant in vitro and in vivo
University of Ottawa × Unknown
42 grants totalling $5.4M
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
1,000 grants totalling $348.9M
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Quantum Valley Ideas Laboratories | $1.2M | Collaborative Science, Technology and In... |
| Centre for Commercialization of Cancer Immunotherapy | $1.0M | Collaborative Science, Technology and In... |
| Centre for Commercialization of Cancer Immunotherapy | $1.0M | Collaborative Science, Technology and In... |
| Mitacs inc. | $1.0M | Collaborative Science, Technology and In... |
| Mitacs inc. | $1.0M | Collaborative Science, Technology and In... |